logo-loader
viewBT Group PLC

BT Group to consolidate its offices across the UK from 300 current locations to around 30 sites

The FTSE 100-listed telecom and broadband provider said Belfast, Birmingham, Bristol, Cardiff, Edinburgh, Ipswich, London and Manchester would be key locations for the group

BT Building
BT, which announced in May 2018 that it would exit its St Paul’s headquarters, said it is currently identifying a new home for the business in London

BT Group PLC (LON:BT.A) revealed on Wednesday that it will consolidate its offices across the UK from 300 current locations to around 30 sites as it moves out of its St Paul's headquarters in the City of London.

In a news release on its corporate website, the FTSE 100-listed telecom and broadband provider said Belfast, Birmingham, Bristol, Cardiff, Edinburgh, Ipswich, London and Manchester would be key locations for the group.

READ: BT upgraded to 'overweight' by Credit Suisse

The group said these will be the first eight of the locations that will house its workplaces of the future as part of a three-to-five-year programme initially announced in May 2018 to improve and consolidate its workplaces across the UK.

The firm announced in May 2018 that would exit its St Paul’s headquarters and said in today’s statement that it is currently identifying a new home for the business in the capital.

It said also that its telephone exchanges will be retained by the group and gave no indication of the impact of the moves on jobs.

BT Group chief executive Philip Jansen commented: “Revealing these eight locations is just the first step; we have dedicated teams working on identifying the best buildings to move into and which ones to redesign for the future.”

Quick facts: BT Group PLC

Price: 104.1591 GBX

LSE:BT.A
Market: LSE
Market Cap: £10.33 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

OKYO Pharma appoints top Beverly Hills surgeon to lead its Scientific...

Dr James Khodabakhsh MD speaks to Proactive's Andrew Scott following his appointment as chair of OKYO Pharma's (LON:OKYO) Scientific Advisory Board. He'll be tasked with bringing together a small group of leaders to review and inform the company's plans to progress its lead product candidate...

3 hours ago

2 min read